Accessibility Menu
Contineum Therapeutics logo

Contineum Therapeutics(NASDAQ) CTNM

Market Cap$529.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-8%
5 YearN/A
1 Year+157%
1 Month-0%
$14.61
+3.18%
+0.45Today
Contineum Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 14.162026-07-28
Contineum Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.87%USD 13.902026-07-21
1 month-0.21%USD 14.192026-06-26
3 month+17.61%USD 12.042026-04-29
Year to date+23.88%USD 11.432025-12-31
1 year+156.99%USD 5.512025-07-28
Since inception-8.05%USD 15.402024-04-05

Contineum Therapeutics Financials at a Glance

Market Cap

$529.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$58.44M

EPS (TTM)

-$1.95

P/E Ratio

-7.25

Dividend

$0.00

Beta (Volatility)

0.65 (Low)

Price

$14.61

Volume

102,724.985

Open

$14.15

Previous Close

$14.16

Daily Range

$13.90 - $14.74

52-Week Range

$5.07 - $16.91

Estimated Earnings Date

Aug 4, 2026

CTNM News

Foolcom-Featured.png

Contineum (CTNM) Q2 R&D Jumps 78%

Motley Fool Markets TeamAug 5, 2025

CTNM: Motley Fool Moneyball Superscore

49

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Contineum Therapeutics

Contineum makes oral drugs for brain and immune system diseases. Its main treatments help people with lung scarring and long-term pain. These pills target specific paths in the body to slow down sickness.

Molecules Targeting Serious Illness

  • PIPE-791: Oral small molecule designed to stop lung tissue scarring and chronic pain; currently in Phase 2 clinical trials.
  • PIPE-307: Selective pill for treating depression and multiple sclerosis; developed through a global collaboration with J&J.
  • CTX-343: Experimental drug for treating tissue scarring outside the brain; development is currently on hold.

Key Partnerships and Milestones

  • Signed a worldwide licensing deal with Janssen Pharmaceutica NV in February 2023 to develop PIPE-307.
  • Received a $25 million equity investment from Johnson & Johnson Innovation - JJDC, Inc. during the 2023 partnership.
  • Launched the Phase 2 global clinical trial for PIPE-791 in December 2025 to treat lung scarring.
  • Reported top-line results from a Phase 1b brain imaging study in September 2025.
  • Announced a strategic decision in 2025 to pause development of two secondary drug programs to save costs.

How the Science Differs

Contineum uses medicinal chemistry to create drugs that can cross the brain's protective barrier. This allows them to treat nervous system disorders and immune-related inflammation with the same oral molecule.

Checking the Progress

  • Revenue remained at $0 in Q4 2025, matching the previous year's performance.
  • Operating income was -$17.1 million in Q4 2025, down 120.2% from $84.7 million in Q4 2024.
  • Net income reached -$15.2 million in Q4 2025, worsening by 4.1% year-over-year.
  • Operating cash flow was -$13 million in Q4 2025, worsening by 27.8% from the previous year.
  • Free cash flow hit -$13.1 million in Q4 2025, a decrease of 26.2% from Q4 2024.

Bottom Line

Contineum has transitioned from a discovery-stage firm to a clinical-stage biotech with a major global pharmaceutical partner. Its future depends on advancing its two lead drugs through high-stakes human trials.

AI Generated • May 5, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

51

CEO

Carmine N. Stengone, MBA

Website

www.contineum-tx.com

Headquarters

San Diego, CA 92121, US

CTNM Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-27.09%

Return on Capital

-25.28%

Return on Assets

-22.36%

Earnings Yield

-13.79%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$529.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

37.39M

Volume

102.72K

Avg. Volume

304.02K

Financials (TTM)

Gross Profit

-$79.00K

Operating Income

-$66.85M

EBITDA

-$58.12M

Operating Cash Flow

-$57.17M

Capital Expenditure

-$496.00K

Free Cash Flow

-$57.66M

Cash & ST Invst.

$246.33M

Total Debt

$6.95M

Contineum Therapeutics Performance Analysis

Contineum Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 50,000,000N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Contineum Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Contineum Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.97N/A
20232023-12-31USD 0.13N/A
20242024-12-31USD -1.63N/A
20252025-12-31USD -2.1732.5%
Contineum Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-3027.4%
Q42025-12-31-8.9%
Q12026-03-3120.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$529.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$10.38M

N/A

Employees

51

N/A

Net Income

-$14.46M

+9.6%

EBITDA

-$14.37M

+9.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$246.33M

+29.2%

Total Debt

$6.95M

+15.9%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$4.65M

+2.3%

Short Term Debt

$2.30M

+58.3%

Return on Assets

-22.36%

N/A

Return on Invested Capital

-26.25%

N/A

Free Cash Flow

-$16.58M

-14.7%

Operating Cash Flow

-$16.27M

-12.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SLNSilence Therapeutics plc
$11.74+1.65%
KYTXKyverna Therapeutics, Inc.
$7.22-3.60%
CAPRCapricor Therapeutics, Inc.
$6.57+0.00%
CADLCandel Therapeutics, Inc.
$9.71+0.31%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOFISoFi Technologies
$15.62-0.07%
INTCIntel
$86.55+0.00%
NVDANvidia
$195.08-0.01%
FFord Motor Company
$15.61+0.04%

Questions About CTNM

What is the current price of Contineum Therapeutics?

Contineum Therapeutics is trading at $14.66 per share.

What is the 52-week range for Contineum Therapeutics?

Over the past 52 weeks, Contineum Therapeutics has traded between $5.07 and $16.91.

How much debt does Contineum Therapeutics have?

As of the most recent reporting period, Contineum Therapeutics reported total debt of $6.95M.

How much cash does Contineum Therapeutics have on hand?

Contineum Therapeutics reported $20.16M in cash and cash equivalents in its most recent financial results.

What is Contineum Therapeutics’s dividend yield?

Contineum Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services